Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUSNASDAQ:ACTUNASDAQ:AUTLNASDAQ:PHVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.44+2.8%$3.28$2.63▼$4.73$657.73M1.45987,542 shs379,199 shsACTUActuate Therapeutics$9.15+1.1%$7.49$5.51▼$11.73$178.72MN/A46,981 shs26,606 shsAUTLAutolus Therapeutics$1.34-4.0%$1.62$1.11▼$5.00$355.24M2.061.47 million shs1.36 million shsPHVSPharvaris$16.97-0.5%$14.94$11.51▼$25.50$905.82M-2.8472,832 shs175,680 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+1.52%+4.05%-4.57%-0.30%+22.34%ACTUActuate Therapeutics+1.12%+8.12%+14.56%-2.58%+904,999,900.00%AUTLAutolus Therapeutics+4.51%-3.47%-16.27%-36.82%-65.25%PHVSPharvaris+1.31%+17.66%+7.97%-5.22%-26.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma1.9959 of 5 stars3.50.00.00.02.62.50.6ACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAUTLAutolus Therapeutics2.6937 of 5 stars3.51.00.00.03.33.30.6PHVSPharvaris2.2588 of 5 stars3.53.00.00.03.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5060.12% UpsideACTUActuate Therapeutics 3.00Buy$20.50124.04% UpsideAUTLAutolus Therapeutics 3.00Buy$9.32598.13% UpsidePHVSPharvaris 3.00Buy$39.00129.79% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, PHVS, ABUS, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/21/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.001/31/2025PHVSPharvarisJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$46.00 ➝ $55.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M106.58N/AN/A$0.63 per share5.45ACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AAUTLAutolus Therapeutics$10.12M35.10N/AN/A$0.64 per share2.09PHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$72.85M-$0.38N/AN/AN/A-1,137.65%-68.18%-51.55%5/1/2025 (Estimated)ACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/AAUTLAutolus Therapeutics-$208.38M-$0.86N/AN/AN/AN/A-63.65%-36.54%5/8/2025 (Estimated)PHVSPharvaris-$109.18M-$2.68N/AN/AN/AN/A-38.52%-36.69%5/14/2025 (Estimated)Latest ACTU, PHVS, ABUS, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PHVSPharvaris-$0.80N/AN/AN/AN/AN/A5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24N/AN/AN/A$1.59 millionN/A5/1/2025Q1 2025ABUSArbutus Biopharma-$0.09N/AN/AN/A$2.54 millionN/A4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AACTUActuate TherapeuticsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A7.027.02ACTUActuate TherapeuticsN/A1.681.68AUTLAutolus TherapeuticsN/A13.6913.69PHVSPharvarisN/A19.0819.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ACTUActuate TherapeuticsN/AAUTLAutolus Therapeutics72.83%PHVSPharvarisN/AInsider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ACTUActuate Therapeutics69.34%AUTLAutolus Therapeutics25.70%PHVSPharvaris11.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.48 million181.91 millionOptionableACTUActuate Therapeutics1019.53 millionN/AN/AAUTLAutolus Therapeutics330266.09 million197.71 millionOptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableACTU, PHVS, ABUS, and AUTL HeadlinesRecent News About These CompaniesPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Here's WhyApril 27 at 12:16 PM | marketbeat.comRock Springs Capital Management LP Purchases 18,200 Shares of Pharvaris (NASDAQ:PHVS)April 23, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Up 7.8% - Still a Buy?April 17, 2025 | marketbeat.comFmr LLC Has $103.43 Million Holdings in Pharvaris (NASDAQ:PHVS)April 16, 2025 | marketbeat.comPharvaris: Buy Rating Backed by Clinical Progress, Market Potential, and Strong Financial PositionApril 14, 2025 | tipranks.comQ1 Earnings Estimate for Pharvaris Issued By Leerink PartnrsApril 12, 2025 | marketbeat.comWedbush Comments on Pharvaris' Q1 Earnings (NASDAQ:PHVS)April 12, 2025 | marketbeat.comWhat is Wedbush's Estimate for Pharvaris FY2029 Earnings?April 11, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Hits New 12-Month Low - Here's What HappenedApril 11, 2025 | marketbeat.comPharvaris’s Strategic Advancements and Strong Financial Position Drive Buy RatingApril 10, 2025 | tipranks.comPharvaris (NASDAQ:PHVS) Stock Price Down 8.4% - Here's What HappenedApril 9, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Announces Quarterly Earnings Results, Beats Expectations By $0.06 EPSApril 9, 2025 | marketbeat.comPharvaris reports Q4 EPS (EUR 0.64) vs. (EUR 0.95) last yearApril 8, 2025 | markets.businessinsider.comPharvaris Reports 2024 Financial Results and Business ProgressApril 8, 2025 | tipranks.comPharvaris Positioned for Growth with Successful Trial and Strong Financials, Analyst Projects Significant Market ExpansionApril 7, 2025 | tipranks.comPharvaris Reports 2024 Financial Results and Advances HAE Treatment StudiesApril 7, 2025 | tipranks.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | gurufocus.comPharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | globenewswire.comPharvaris (NASDAQ:PHVS) Sets New 12-Month Low - Time to Sell?April 5, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - What's Next?April 4, 2025 | marketbeat.comPharvaris (NASDAQ:PHVS) Stock Price Down 4.3% - What's Next?April 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Intel-Taiwan Semiconductor Alliance Fuels Turnaround HopesBy Jeffrey Neal Johnson | April 8, 2025View Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomThe Ecosystem Edge: Joby's Competitive AdvantageBy Jeffrey Neal Johnson | April 4, 2025View The Ecosystem Edge: Joby's Competitive AdvantageGoodyear Gains Traction: Shares Climb as Key Catalysts AlignBy Jeffrey Neal Johnson | April 7, 2025View Goodyear Gains Traction: Shares Climb as Key Catalysts AlignACTU, PHVS, ABUS, and AUTL Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.44 +0.10 (+2.84%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Actuate Therapeutics NASDAQ:ACTU$9.15 +0.10 (+1.10%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Autolus Therapeutics NASDAQ:AUTL$1.34 -0.06 (-3.96%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Pharvaris NASDAQ:PHVS$16.97 -0.09 (-0.52%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
